DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
PEGYLATED CARBOXYHEMOGLOBIN (BOVINE)
2
Unknown
Investigational
Unknown
Unknown
Ischemic Stroke; Renal Insufficiency, Chronic; Anemia, Sickle Cell; Skin Ulcer
Unknown
PEGYLATED CARBOXYHEMOGLOBIN (BOVINE)
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRILIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 negative modulator
PRILIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NRX194204
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
NRX194204
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG 592
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
AMG 592
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DS107G
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DS107G
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APILIMOD MESYLATE
2
Unknown
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Crohn Disease
1-phosphatidylinositol 3-phosphate 5-kinase inhibitor
APILIMOD MESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
5G3P5OK11S
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MERIMEPODIB
2
Small molecule
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Inosine-5'-monophosphate dehydrogenase 1 inhibitor
MERIMEPODIB
×
Maximum Phase:
2
First Approval:
None
UNII:
2ZL2BA06FU
Molecule Type:
Small molecule
Molecular Formula:
C23H24N4O6
Molecular Weight:
452.47
AlogP:
4.01
PSA:
123.95
HBD:
3.0
HBA:
#RotB:
7.0
Source:
DORAMAPIMOD
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Psoriasis
MAP kinase p38 alpha inhibitor
DORAMAPIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
HO1A8B3YVV
Molecule Type:
Small molecule
Molecular Formula:
C31H37N5O3
Molecular Weight:
527.67
AlogP:
5.99
PSA:
80.65
HBD:
2.0
HBA:
#RotB:
7.0
Source:
TAT
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
TAT
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LADEMIRSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Unknown
microRNA 21 antisense inhibitor
LADEMIRSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
KKQ6AQN9LH
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
T-2000
2
Small molecule
Investigational
Unknown
Unknown
Essential Tremor
Unknown
T-2000
×
Maximum Phase:
2
First Approval:
None
UNII:
QW2J7VST60
Molecule Type:
Small molecule
Molecular Formula:
C20H20N2O5
Molecular Weight:
368.39
AlogP:
1.97
PSA:
76.15
HBD:
0.0
HBA:
#RotB:
6.0
Source:
CARRAGEENAN
2
Unknown
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome; Conjunctivitis, Viral; Papillomavirus Infections
Unknown
CARRAGEENAN
×
Maximum Phase:
2
First Approval:
None
UNII:
5C69YCD2YJ
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BPN-14770
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BPN-14770
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARBACLOFEN PLACARBIL
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Back Pain; Gastroesophageal Reflux; Muscle Spasticity; Multiple Sclerosis
GABA-B receptor agonist
ARBACLOFEN PLACARBIL
×
Maximum Phase:
2
First Approval:
None
UNII:
W89H91R7VX
Molecule Type:
Small molecule
Molecular Formula:
C19H26ClNO6
Molecular Weight:
399.87
AlogP:
3.81
PSA:
101.93
HBD:
2.0
HBA:
#RotB:
9.0
Source:
TEBENTAFUSP
2
Protein
Investigational
Unknown
Unknown
Melanoma
Melanocyte protein PMEL binding agent
TEBENTAFUSP
×
Maximum Phase:
2
First Approval:
None
UNII:
N658GY6L3E
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVN-944
2
Small molecule
Investigational
Unknown
Unknown
Pancreatic Neoplasms
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
AVN-944
×
Maximum Phase:
2
First Approval:
None
UNII:
I3NPL1V48Q
Molecule Type:
Small molecule
Molecular Formula:
C25H27N5O5
Molecular Weight:
477.52
AlogP:
5.47
PSA:
138.51
HBD:
3.0
HBA:
#RotB:
9.0
Source:
LY-295501
2
Small molecule
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Unknown
LY-295501
×
Maximum Phase:
2
First Approval:
None
UNII:
240Y4YO0TN
Molecule Type:
Small molecule
Molecular Formula:
C15H12Cl2N2O4S
Molecular Weight:
387.24
AlogP:
3.44
PSA:
84.5
HBD:
2.0
HBA:
#RotB:
3.0
Source:
ACALISIB
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms
PI3-kinase p110-delta subunit inhibitor
ACALISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
OVW60IDW1D
Molecule Type:
Small molecule
Molecular Formula:
C21H16FN7O
Molecular Weight:
401.41
AlogP:
3.36
PSA:
101.38
HBD:
2.0
HBA:
#RotB:
4.0
Source:
PARTHENOLIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PARTHENOLIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
2RDB26I5ZB
Molecule Type:
Small molecule
Molecular Formula:
C15H20O3
Molecular Weight:
248.32
AlogP:
2.76
PSA:
38.83
HBD:
0.0
HBA:
#RotB:
0.0
Source:
AG0302-COVID19
2
Unknown
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
AG0302-COVID19
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SOVAPREVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus serine protease, NS3/NS4A inhibitor
SOVAPREVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
2ND9V3MN6O
Molecule Type:
Small molecule
Molecular Formula:
C43H53N5O8S
Molecular Weight:
799.99
AlogP:
4.99
PSA:
164.31
HBD:
2.0
HBA:
#RotB:
13.0
Source:
HUMAX-IL15
2
Antibody
Investigational
Unknown
Unknown
Unknown
Lymphocyte differentiation antigen CD38 inhibitor
HUMAX-IL15
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BISANTRENE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Alpha-ketoglutarate-dependent dioxygenase FTO inhibitor
BISANTRENE
×
Maximum Phase:
2
First Approval:
None
UNII:
39C34M111K
Molecule Type:
Small molecule
Molecular Formula:
C22H22N8
Molecular Weight:
398.47
AlogP:
1.76
PSA:
97.56
HBD:
4.0
HBA:
#RotB:
4.0
Source:
PHOSPHOCREATINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PHOSPHOCREATINE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CE-326597
2
Small molecule
Investigational
Unknown
Unknown
Obesity
Cholecystokinin A receptor agonist
CE-326597
×
Maximum Phase:
2
First Approval:
None
UNII:
1FGZ6L9SF2
Molecule Type:
Small molecule
Molecular Formula:
C37H34N6O2
Molecular Weight:
594.72
AlogP:
6.53
PSA:
87.12
HBD:
1.0
HBA:
#RotB:
8.0
Source:
LEXAPTEPID PEGOL
2
Unknown
Investigational
Unknown
Unknown
Anemia
Unknown
LEXAPTEPID PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
CTL75X0V60
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DNK333
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic; Irritable Bowel Syndrome
Neurokinin 1 receptor antagonist
DNK333
×
Maximum Phase:
2
First Approval:
None
UNII:
G9BL4978MZ
Molecule Type:
Small molecule
Molecular Formula:
C27H25Cl2F6N3O3
Molecular Weight:
624.41
AlogP:
6.06
PSA:
78.51
HBD:
2.0
HBA:
#RotB:
7.0
Source:
BAICALEIN
2
Small molecule
Investigational
Unknown
Unknown
Influenza, Human
Unknown
BAICALEIN
×
Maximum Phase:
2
First Approval:
None
UNII:
49QAH60606
Molecule Type:
Small molecule
Molecular Formula:
C15H10O5
Molecular Weight:
270.24
AlogP:
2.58
PSA:
90.9
HBD:
3.0
HBA:
#RotB:
1.0
Source:
FLOTETUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Interleukin-3 receptor subunit alpha binding agent
FLOTETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0AHT0IC02G
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OPICINUMAB
2
Antibody
Investigational
Unknown
Unknown
Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Optic Neuritis
Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitor
OPICINUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
WX1WTN0Y15
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMISELIMOD HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Inflammatory Bowel Diseases; Lupus Erythematosus, Systemic; Colitis, Ulcerative; Crohn Disease; Multiple Sclerosis, Relapsing-Remitting; Psoriasis
Sphingosine 1-phosphate receptor modulator
AMISELIMOD HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
AY898D6RU1
Molecule Type:
Small molecule
Molecular Formula:
C19H31ClF3NO3
Molecular Weight:
413.91
AlogP:
3.67
PSA:
75.71
HBD:
3.0
HBA:
#RotB:
12.0
Source:
LERIGLITAZONE
2
Small molecule
Investigational
Unknown
Unknown
Friedreich Ataxia
Peroxisome proliferator-activated receptor gamma agonist
LERIGLITAZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
K824X25AYA
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O4S
Molecular Weight:
372.45
AlogP:
2.65
PSA:
88.52
HBD:
2.0
HBA:
#RotB:
7.0
Source:
NAVARIXIN
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Psoriasis; Pulmonary Disease, Chronic Obstructive
Interleukin-8 receptor A antagonist
NAVARIXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
7V3BY6G538
Molecule Type:
Small molecule
Molecular Formula:
C21H23N3O5
Molecular Weight:
397.43
AlogP:
2.9
PSA:
111.88
HBD:
3.0
HBA:
#RotB:
7.0
Source:
PYRUVATE
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Prostatic Neoplasms
Unknown
PYRUVATE
×
Maximum Phase:
2
First Approval:
None
UNII:
8558G7RUTR
Molecule Type:
Small molecule
Molecular Formula:
C3H4O3
Molecular Weight:
88.06
AlogP:
-0.34
PSA:
54.37
HBD:
1.0
HBA:
#RotB:
1.0
Source:
DECERNOTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Tyrosine-protein kinase JAK3 inhibitor
DECERNOTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
MZK2GP0RHK
Molecule Type:
Small molecule
Molecular Formula:
C18H19F3N6O
Molecular Weight:
392.39
AlogP:
3.28
PSA:
95.59
HBD:
3.0
HBA:
#RotB:
6.0
Source:
1
2
…
141
142
143
144
145
146
147
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA